The Library
Radiobiological modelling of the therapeutic ratio for the addition of synchronous chemotherapy to radiotherapy in locally advanced squamous cell carcinoma of the head and neck
Tools
Tools
Tools
Hartley, A., Sanghera, P., Glaholm, J., Mehanna, Hisham M., McConkey, C. and Fowler, J. (2010) Radiobiological modelling of the therapeutic ratio for the addition of synchronous chemotherapy to radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Clinical Oncology, Vol.22 (No.2). pp. 125-130. doi:10.1016/j.clon.2009.10.004 ISSN 0936-6555.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1016/j.clon.2009.10.004
Abstract
Aims: To model the therapeutic gain from the addition of synchronous chemotherapy to radiotherapy in locally advanced head and neck cancer.
Materials and methods: Refinements to previous methodology, including the derivation of weighted estimates of key parameters from randomised studies and the use of the expected mucosal biologically effective dose concept, have been used to produce an evidence-based assessment of the benefit from the addition of chemotherapy when considering acute grade 3 mucositis and rates of 5-year local control.
Results: For a value of alpha = 0.3Gy(-1) the additional contribution from chemotherapy to local control was estimated to be 9.3 Gy(10) and to grade 3 mucositis 6.4 Gy(10). The additional expected mucosal biologically effective dose if radiotherapy dose escalation had been used instead of chemotherapy would have been 11.6 Gy(10). Therefore, the mucosal sparing by using synchronous chemotherapy rather than radiotherapy dose escalation was found to be 5.2 Gy(10) or the equivalent dose in 2 Gy fractions 4.3 Gy EQD(2).
Conclusion: This modelling suggests a small therapeutic gain for the use of synchronous chemotherapy instead of radiotherapy dose escalation. This conclusion is dependenton the linear quadratic model and takes no account of late side-effects. This gain would be greater for agents that enhance the mucosal reaction to a lesser degree. This gain may be less when data for radiotherapy dose escalation to smaller high dose volumes using intensity-modulated radiotherapy are considered. (C) 2009 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||
| Journal or Publication Title: | Clinical Oncology | ||||
| Publisher: | Elsevier Science London | ||||
| ISSN: | 0936-6555 | ||||
| Official Date: | March 2010 | ||||
| Dates: |
|
||||
| Volume: | Vol.22 | ||||
| Number: | No.2 | ||||
| Number of Pages: | 6 | ||||
| Page Range: | pp. 125-130 | ||||
| DOI: | 10.1016/j.clon.2009.10.004 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
